Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Orlando, Florida

Phase 1 cancer trials in Orlando, FL

41 Phase 1 cancer studies are recruiting participants at sites in Orlando as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Orlando at a glance

  • 41 studies are recruiting at a site in Orlando.
  • By phase: Phase 1 (21), Phase 1/2 (20).
  • By sponsor: industry (39), university, hospital or other (2).
  • By research area: Lung Cancer (18), Breast Cancer (16), Lymphoma (4), Prostate Cancer (2), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Orlando

Basic details from each study's public record (the 30 most recently updated of 41). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Study site
    Advent Health Medical Group Radiation Oncology at Central Florida
    Registry record
    NCT07020117 · updated
  2. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Sarah Cannon Research Institute at Florida Cancer Specialists
    Registry record
    NCT06638307 · updated
  3. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    AdventHealth Cancer Institute
    Registry record
    NCT06586957 · updated
  4. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Compass Therapeutics
    Study site
    Florida Cancer Specialists - Lake Nona
    Registry record
    NCT06150664 · updated
  5. Study of XB010 in Subjects With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Sarah Cannon Research Institute at Florida Cancer Specialists
    Registry record
    NCT06545331 · updated
  6. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Terremoto Biosciences Inc.
    Study site
    Florida Cancer Specialists - Lake Nona
    Registry record
    NCT07109726 · updated
  7. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sutro Biopharma, Inc.
    Study site
    SCRI at Florida Cancer Specialists
    Registry record
    NCT07807345 · updated
  8. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Sarah Cannon Research Institute - Lake Nona Florida
    Registry record
    NCT06293898 · updated
  9. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Advent Health
    Registry record
    NCT04585750 · updated
  10. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Sara Cannon Research Institute Lake Nona
    Registry record
    NCT05983432 · updated
  11. ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Avenzo Therapeutics, Inc.
    Study site
    Avenzo Therapeutics Recruiting Site
    Registry record
    NCT06998407 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Orlando, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Orlando

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Sarah Cannon Research Institute at Florida Cancer Specialists
    Registry record
    NCT07277413 · updated
  2. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
    Registry record
    NCT06914128 · updated
  3. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Orlando Health Cancer Institute ( Site 0108)
    Registry record
    NCT07227597 · updated
  4. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Sarah Cancer Research Institution - Florida Cancer Specialist
    Registry record
    NCT06706076 · updated
  5. SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Florida Cancer Specialists Lake Nona
    Registry record
    NCT07857616 · updated
  6. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Study sites
    Advent Health Orlando · Orlando Health Cancer Institute (Melanoma/NSCLC)
    Registry record
    NCT06060613 · updated
  7. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  8. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    DualityBio Inc.
    Registry record
    NCT05914116 · updated
  9. AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Avenzo Therapeutics, Inc.
    Study site
    Avenzo Therapeutics Recruiting Site
    Registry record
    NCT07038343 · updated
  10. Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Orlando Health Ambulatory Care Center · Orlando Health Cancer Institute · Orlando Health Orlando Regional Medical Center
    Registry record
    NCT07227298 · updated
  11. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Advent Health Orlando
    Registry record
    NCT06362252 · updated
  12. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    Sarah Cannon Research Institute - Florida Cancer Specialists
    Registry record
    NCT04913285 · updated
  13. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Sarah Cannon Research Institute at Florida Cancer Specialists
    Registry record
    NCT05245500 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Orlando, FL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Orlando

  1. A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Genentech, Inc.
    Study site
    Sarah Cannon Research Institute @ Florida Cancer
    Registry record
    NCT05800665 · updated
  2. A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    AstraZeneca
    Registry record
    NCT07192614 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Orlando, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Orlando

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Arnold Palmer Hospital for Children · Nemours Children's Hospital
    Registry record
    NCT04726241 · updated
  2. A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment

    • Phase 1
    • Ages 18 to 80
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Orlando Clinical Research Center
    Registry record
    NCT07853040 · updated
  3. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Study site
    Arnold Palmer Hospital for Children
    Registry record
    NCT05848687 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Orlando, FL on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Orlando

  1. A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Florida Cancer Specialists
    Registry record
    NCT07186842 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Orlando, FL on ClinicalTrials.gov.

Ask about studies near Orlando

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call